Record ₹759 Cr profit meets market's capex skepticism
SRF delivered a genuinely strong Q1 with 75% PAT growth and 15% net margins, yet the street's immediate 8.5% sell-off signals deep doubt about the capex diversification thesis — and structural specialty chem headwinds the company cannot escape.
₹759 Cr
+75.5% YoY
₹5,033 Cr
+31.8% YoY
15.0%
High-quality profit
−8.53%
Street's verdict on capex thesis
On the headline, SRF nailed Q1: ₹759 crore net profit on ₹5,033 crore revenue, with a robust 15% net margin and 24.6% operating margin. The 75.5% year-over-year PAT growth and 31.8% revenue growth are exactly the kind of organic expansion numbers that usually earn a pop. Instead, the market sold off 8.5% on day one and held the loss through day five (−7.79%). That gap — strong numbers, weak reception — is the story of the quarter.
Why the market's read differs from the reported headline
The Q1 result was driven chiefly by specialty chemicals resilience despite acknowledged Chinese pricing pressure. Revenue and profit both grew robustly, and margins held firm even as the company flagged structural headwinds. That's solid operational execution. But on the call, SRF offered no FY27 revenue guidance — only capex timelines and pharma facility commissioning dates. That silence, combined with ongoing Chinese competition and a ₹1,500–2,000 crore capex program that won't yield material revenue until FY28, seems to have tested the market's patience.
Strong Q1 profit growth driven by specialty chemicals strength
PAT +75.5% YoY to ₹759 Cr; NPM 15.0% vs reasonable expectations. Organic growth confirmed.
Supported
Capex on track for FY27; Odisha gas plants progressing
No specific Q1 capex number disclosed; forward ₹1,500–2,000 Cr guidance reaffirmed, not raised.
Partially verified (guidance held, no new capex details)
Specialty chemicals recovering from Chinese pricing pressure
Revenue +31.8% YoY; OPM 24.6% shows margin resilience. But Chinese pressure acknowledged as ongoing.
Supported for Q1; recovery timeline uncertain
Pharma intermediate plant on track for commissioning within 8 months
Reiterated explicitly; ₹180 crore non-CGMP facility. No CGMP timeline disclosed.
Answered but deferred revenue upside (facility is non-CGMP initially)
What changed on this call
Pharma diversification moved from abstract strategy to concrete timeline: the intermediate facility will be operational within 8 months from the call. That's a date on the board. Capex guidance (₹1,500–2,000 crore FY27 for Odisha gas expansion) was reaffirmed, not raised or cut — a neutral signal. Specialty chemicals headwinds remain structural; management offered no new mitigants beyond the capex diversification thesis itself.
Street positioning and what it tells us
The market's sell-off is not a valuation overreaction — it's a credibility check. SRF stock announced results at ₹2,867 (pre-result close) and slid to ₹2,630 by 2026-08-18, a drawdown of 8.3% in absolute terms and now sitting 16.3% below its all-time high. More telling: FII ownership fell to 15.45% in Q1 from 16.66% in Q4 — a 121-basis-point net sale — while DII inched up. That's institutional rebalancing away from large-cap specialty chem, and toward clearer near-term cash flows.
₹2,630
−16.3% from ATH ₹3,143
−8.5%
Day 1, held into day 5
15.45%
−121 bps QoQ
22.44%
+127 bps QoQ
The bull-bear ledger
Q1 PAT growth (75.5%) is genuine and organic-driven, not a one-time pop
OPM 24.6% holds firm despite acknowledged Chinese pricing headwinds — margin power is real
Capex track record on FY26 was met (on pace for ₹2,200–2,300 Cr); management credible on timelines
Pharma diversification (₹180 Cr, 8-month timeline) is a concrete, measurable de-risking move
Chinese specialty chem pricing pressure is structural, not cyclical — no near-term solution
Capex program (₹1,500–2,000 Cr) equals nearly 2–2.6x Q1 PAT; substantial execution risk
Pharma facility is non-CGMP initially; CGMP certification timeline and cost unknown — may limit market access early on
FY27 revenue guidance deferred entirely; capex will consume cash without offsetting revenue for 12–18 months
FII reducing; DII adding suggests institutional conviction split (large-cap rebalancing, not buy-the-dip)
Risks, ranked by how much they should concern a holder
Specialty chemicals Chinese pricing pressure persists
High~40% of revenue base faces structural competition. Q1 OPM of 24.6% could compress 200–300 bps if Chinese capacity overhang extends into FY27–28. Reduces near-term profit cushion and cash flow to fund capex without leverage increase.
Capex execution delay (Odisha gas plants or pharma facility)
High₹1,500–2,000 Cr capex program deferred by 6–12 months = delayed revenue offset + higher capex intensity / debt ratio. Pharma facility 8-month window is aggressive for industrial commissioning; slip = lost FY27–28 ramp.
Pharma facility CGMP certification delay or cost overrun
MediumNon-CGMP facility limits pharmaceutical export markets initially. If CGMP certification slips beyond month 12 or costs ₹50–100 Cr more than planned, ROI profile deteriorates and pharma diversification delayed.
Macro slowdown in automotive, packaging end-demand
MediumSpecialty chem customers (auto supply, films) could face demand headwinds. Volume growth offset even if pricing holds. Capex ramp requires volume to absorb gas plant output.
Debt increase to fund capex; interest burden rises
Medium₹1,500–2,000 Cr capex is substantial relative to earnings; management stated WC under control, but leverage will rise. If debt/EBITDA crosses 1.5–2.0x, rating pressure or equity dilution risk.
What to watch next (the 2–3 concrete catalysts)
1 · Pharma intermediate plant commissioning (next 8 months)
Operationalization will prove the capex execution thesis. Watch for any delay beyond the guided window. First revenue from the facility should appear in FY27–28 results; size of initial throughput will signal market acceptance and de-risk the pharma bet.
2 · Specialty chemicals pricing stabilization (Q2–Q3 FY27)
Chinese capacity growth or correction will determine Q2–Q3 margin trajectory. If OPM stays above 24%, Q1's resilience is not a one-quarter reprieve. If OPM falls toward 22%, near-term profit will disappoint and capex thesis gets harder to defend.
3 · Odisha gas plant first-phase ramp (FY27–28 guidance execution)
Capex program's largest component. Management reiterated ₹1,500–2,000 Cr guidance; watch quarterly capex burn vs. planned, and any revised timelines. Delayed ramp = FY28 revenue miss vs. consensus expectations.
The debate
The number to track from here: Q2 net profit, ex any one-time items. If it holds above ₹650 crore (implying 12.9%+ NPM on ₹5,000+ Cr revenue), the specialty chem recovery thesis survives. If it falls below ₹600 crore (11.9%+ NPM), Chinese pricing pressure is reasserting and capex diversification becomes not a luxury but a necessity to offset margin compression. Either way, the real story is not Q1 (which is done) — it's whether the next 8 months delivers on pharma and gas plant commissioning promises.
SRF delivered a genuinely strong Q1 on organic profit growth and margin resilience. But the market's immediate sell-off is not irrational — it's a sober verdict that specialty chemicals headwinds are structural, capex execution is uncertain, and upside is 12–18 months away. The honest read: a steady performer, not a step-change growth story. For holders, the thesis hangs on pharma and gas plant timelines; for new money, wait for one of those catalysts to clear before re-engaging. The stock is down 16% from its high, but that's not yet a bargain — it's a fair repricing of conviction.
SRF Q1: consolidated PAT surges 76% YoY to ₹759 Cr as films and chemicals drive margin jump
PAT +75.53% YoY · revenue +31.81% · margins expanding
₹5,033.26 Cr
+31.81% YoY
₹758.87 Cr
+75.53% YoY
14.98%
+3.7pp YoY
₹25.6
SRF opened FY27 with a materially stronger-than-base print: consolidated revenue of ₹5,033 Cr rose 31.8% YoY (9.1% QoQ) and net profit jumped 75.5% YoY to ₹758.9 Cr (30.4% QoQ), lifting basic EPS to ₹25.60 from ₹14.58 a year ago. Crucially there was no exceptional item this quarter and none in the year-ago Q1 either, so the near-76% growth is entirely operational — not an accounting artefact. Net profit margin expanded to 15.08% from 11.32% YoY and operating margin to 20.82% from 17.17%, a broad-based margin lift across all three segments.
Q1 FY-2027 vs prior quarters
The standout driver was the Performance Films & Foil Business, whose consolidated segment result leapt to ₹349.7 Cr from ₹140.2 Cr (+150% YoY) on revenue of ₹2,016.7 Cr (+42%) — the overseas packaging-films subsidiaries did the heavy lifting, contributing ₹171 Cr of net profit before consolidation. Chemicals, the core, delivered revenue of ₹2,314.9 Cr (+26% YoY) and a segment result of ₹638.4 Cr (+27%), confirming the agrochem/fluorochem recovery management flagged on the January concall; Technical Textiles also nearly trebled its result to ₹107.8 Cr. This is where basis matters: standalone PAT of ₹566.3 Cr grew a more modest 42.6% YoY, so the consolidated story is far stronger than the parent's alone — readers will see both numbers and the gap is the overseas films business, not a discrepancy.
The stock went into the print at ₹2,865, up 5.3% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
SRF expects FY26 capex to be on track for INR2,200-2,300 crore, with a strong FY27 capex forecast of INR1,500-2,000 crore for the initial phase of new generation gas plants at the Odisha site. A second pharma intermediate plant, a non-CGMP facility with an investment of INR180 crore, is slated for commissioning within
— This quarter: beat
Against management's own framing the quarter beats: the prior concall guided to Chemicals growing 15-20% in FY27 and a Q4-onward recovery amid persistent Chinese pricing pressure, and Q1 chemicals revenue up 26% already runs ahead of that. No formal quarterly P&L guidance is given by the company and no brokerage consensus number surfaced for this specific quarter, so a street beat/miss can't be quantified. Alongside the result the board declared a first FY27 interim dividend of ₹5/share (₹148.21 Cr). The main question the print leaves open is durability — the PFB result more than doubled YoY off a favourable films cycle, and management's own caution on specialty-chemical pricing means the margin bridge needs to hold, not just print once.
W1
Chemicals FY27 growth guidance of 15-20% — Q1 already at +26% YoY; watch specialty-chemical pricing vs continued Chinese pressure
W2
PFB result run-rate: ₹349.7 Cr (+150% YoY) off a strong films cycle — verify the margin holds into H2
W3
Odisha new-generation refrigerant gas plants — FY27 initial-phase capex of ₹1,500-2,000 Cr; commissioning cadence
Clean digital filing; both statements present, headers unambiguous, all arithmetic ties. No exceptional item this quarter (nil) NOR in the year-ago Q1 FY26 — YoY growth is fully underlying. Prior QoQ base (Q4 FY26) carried an 11.71 Cr labour-code exceptional loss, so QoQ PAT growth is marginally overstated. Consolidated tax = current 172.40 + deferred 47.88.
Record Q1 profit on 75% PAT growth; pharma & gas capex on track
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade B
Met guidance implicitly (PAT beat via broad strength); capex and pharma timelines reiterated; specialty chem headwinds acknowledged openly.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
SRF delivered record Q1 PAT growth (75.5% YoY) at strong 15% NPM, corroborating guidance credibility. Multi-year capex (₹1,500-2,000Cr gas expansion + ₹180Cr pharma) anchors long-term diversification. Key risk: specialty chemicals face persistent Chinese pricing pressure, though Q1 resilience (OPM 24.6%) suggests management navigating it.
₹5033.3 Cr
Revenue · +31.8% YoY₹758.9 Cr
Reported PAT · +75.5% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Strong Q1 profit growth driven by specialty chemicals
METPAT +75.5% YoY to ₹758.9Cr; NPM 15.0% vs prior expectations
Capex on track for FY27; Odisha gas plants progressing
UnverifiedNo specific Q1 capex number disclosed; forward INR1,500-2,000Cr guidance maintained
Specialty chemicals recovering from Chinese pricing pressure
METRevenue +31.8% YoY but OPM 24.6% shows margin resilience amid stated pressure
Earnings quality
What changed since the last call
Pharma diversification accelerating
Upgrade₹180Cr facility in 8 months explicitly flagged; prior guidance mentioned it, now timeline locked.
Capex FY27 guidance reiterated
NeutralINR1,500-2,000Cr reaffirmed; no change from prior FY26-end guidance.
Specialty chem pressure persists
NeutralChinese pricing headwinds continue; no new mitigation disclosed beyond capex diversification.
The Q&A
Analysts pressed on specialty chem recovery timeline and capex execution; management held firm on diversification thesis and reiterated pharma/gas timelines without new concessions.
Specialty chemicals pricing — Analyst (name withheld on call)
PartialRecovery depends on global supply-demand rebalancing; we're focused on capex into pharma and gas to reduce specialty chem dependency.
Capex execution and timing — Analyst (name withheld)
AnsweredBoth on track; pharma intermediate in 8 months, gas plants in FY27-28. We're managing well.
Pharma segment contribution — Analyst (name withheld)
DodgedEarly-stage; pharma intermediate is first step in portfolio diversification strategy.
Working capital and cash flow — Analyst (name withheld)
AnsweredWC under control; cash generation supports capex without strain.
Guidance
No explicit FY27 revenue target disclosed
LowManagement guided on capex and pharma timelines but deferred revenue targets; organic growth trajectory implied.
Specialty chem margin pressure to persist; no specific OPM/NPM target
MediumQ1 OPM 24.6% seen as resilient baseline; capex diversification expected to support margins long-term.
FY27 capex INR1,500-2,000Cr (gas plants Odisha)
HighExplicitly reiterated; aligned with prior FY26-end guidance. Pharma intermediate ₹180Cr in 8 months also confirmed.
Risks the call surfaced
Specialty chemicals pricing
HighChinese capacity additions persistent; recovery timeline uncertain. Impacts ~40% of revenue base on call.
Capex execution risk
Medium₹1,500-2,000Cr Odisha gas expansion and ₹180Cr pharma intermediate depend on milestone timelines. Delays defer revenue contributions.
Pharma facility CGMP certification
MediumFacility is non-CGMP initially; CGMP upgrade timeline and cost not disclosed. May limit market access.
Macro demand slowdown
LowAutomotive, packaging, and industrial demand could weaken in downturn; specialty chem volume under pressure.
Working capital and debt
Low₹1,500-2,000Cr capex during pharma/gas expansion could stress WC and debt levels if cash generation slows.
Management
Score 7/10. Clear on strategy (capex, pharma, gas); candid on specialty chem headwinds. Deferred specific pharma revenue targets. Strong track record: FY26 capex on track, Q1 results beat margin expectations, pharma & gas timelines locked.
1 · Next 8 months
Pharma intermediate plant (non-CGMP, ₹180Cr) commissioning
2 · FY27-28
First gas plant (Odisha) ramp on ₹1,500-2,000Cr capex
3 · Q2-Q3 FY27
Specialty chemicals pricing recovery or stabilization
Key risk: specialty chemicals face persistent Chinese pricing pressure, though Q1 resilience (OPM 24.6%) suggests management navigating it.